Synthesis and Biological Evaluation of a Novel Series of Pyrazolylcoumarins as Anti-Inflammatory and Antioxidant Agents

Abstract

A new series of pyrazolylcoumarins (4a-k) was synthesized by reaction of appropriate dibromochalcones (3a-k) with phenyl hydrazine in ethanol. Structures of all new synthesized compounds were characterized on the basis of elemental analysis and spectral data (UV, IR and ¹H NMR). The title compounds were screened for in vivo anti-inflammatory activities at a dose of 200 mg/kg b.w. Among the 11 prepared compounds, Compounds 4c, d, h and i exhibited significant anti-inflammatory activity in model of acute inflammation such as carrageenan-induced rat edema paw while compound 4d showed considerable activity in model of chronic inflammation such as adjuvant-induced arthritis along with minimum ulcerogenic index and were compared with diclofenac (13.5 mg/kg b.w.) as a standard drug. Additionally, the synthesized compounds were evaluated for their in vitro antioxidant activity. Compound 4k was found to be the most active antioxidant in the series compared with standard vitamin C.

Key words

DPPH - coumarin - NSAIDs - pyrazole

• References

• 1 Sontag SJ. Prostaglandins in peptic ulcer disease: An overview of current status and future directions. Drug 1986; 32: 445-457
• 2 Allison MC, Howatson AG, Torrance CJ et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749-754
• 3 Flower RJ. The development of COX2 inhibitors. Nature Reviews Drug Discovery 2003; 2: 179-191
• 4 Clive DM, Stoff JS. Renal syndromes associated with non-steroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563-570
• 5 Song Y, Connor DT, Doubleday R et al. Synthesis, structure activity relationship and in-vivo evaluation of substituted ditetrabutyl phenols as a novel class of potent selective and orally active cyclooxygenase-2 inhibitors, 1-thiazolone and Oxazolone series. J Med Chem 1999; 42: 1151-1160
• 6 Chandrasekharan NV, Dai H, Roos KLT et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931
• 7 Palomer A, Cabré F, Pascual J et al. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J Med Chem 2002; 45 (07) 1402-1411
• 8 Gadad AK, Kittur BS, Kapsi SG et al. Synthesis, analgesic and anti-inflammatory activities of some 1-acyl/aracyl-5-aminopyrazole derivatives. Arzneim Forsch 1996; 46: 1082-1085
• 9 Penning TD, Talley JJ et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-5-(4-methylphenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 1997; 40: 1347-1365
• 10 Tsuji K, Nakamura K, Ogino T et al. Studies on anti-inflammatory agents. VI. Synthesis and pharmacological properties of 2,3-diarylthiophenes. Chem Pharm Bull 1998; 46: 279-286
• 11 Connolly PJ, Wetter SK, Beers KN et al. N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett 1999; 9: 979-986
• 12 Boschelli D, Connor D, Bornemeier DA et al. 1,3,4-oxadiazole, 1, 3, 4-thiadiazole, and 1, 2, 4-triazole analogs of the fenamates: In vitro inhibition of cyclooxygenase and 5-lipoxygenase activities. J Med Chem 1993; 36: 1802-1810
• 13 Freeman B, Crop J. Biology of disease, free radicals and tissue injury. Lab Invest 1982; 47: 412-426
• 14 Vane J. The mode of action of asprin-like drugs. Agents React 1978; 6: 430-431
• 15 Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 2^nd ed. Oxford: Clarendon Press; 1989: 427
• 16 Roberfroid M, Viche H, Remede J. Free Radicals in Drug Research. In: Testa B. (ed.). adv. Drug Research Res. Vol 16. Academic Press; London: 1987: 2-43
• 17 Velavan S, Naghlendran K, Mahesh R et al. In vitro antioxidant activity of Asparagus racemosus root. Phcogmag 1998; 26-32
• 18 Kennedy R, Thornes R. Coumarins: Biology, Applications and Mode of Action. Wiley & Sons; Chichester, UK: 1997
• 19 Murray RDH, Mendez J, Brown SA. The Natural Coumarins, Occurrence, Chemistry and Biochemistry. John Wiely & Sons; New York: 1982
• 20 Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE et al. Natural and Synthetic Coumarin Derivatives with Antiinflammatory/Antioxidant Activities. Curr Pharm Design 2004; 10: 3813-3833
• 21 Lacy A, O’Kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 2004; 10: 3797-3811
• 22 Knoevenagel E. Knoevenagel Condensation. Chem Ber 1898; 31: 2596
• 23 Aragade P, Venkatnarayanan R, Maddi VS et al. J. Synthesis and antibacterial activity of a new series of 3-[3-(substituted phenyl)-1-phenyl-1H-pyrazol-5-yl]-2H-chromen-2-one derivative. Enzy Inhib Med Chem 2012; 27: 849-853
• 24 OECD/OCDC, OECD ‘‘Guidelines for Testing of Chemicals’’ Revised Draft Guidelines 423; Acute Oral Toxicity Class Method, Revised Document, October 2000
• 25 Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962; 111: 544-547
• 26 Newbould BB. Chemotherapy of arthritis induced in rats by Mycobacterial adjuvant. Br j pharmacol chemother 1963; 21: 127-136
• 27 Vogel HG. (ed.). Drug Discovery and Evaluation: Pharmacological Assays. third ed. Springer-Verlag; Berlin, Heidelberg: 2002
• 28 Blois MS. Antioxidant determination by the use of a stable free radical. Nature 1958; 181: 1199-1200